Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Somaye Arabzadeh1, Atefeh Zeinoddini1, Seyed-Ali Mostafavi1, Mehdi Hamedi1, Abolfazl Ehyaii1, Ali Ghaleiha2, Arefeh Zeinoddini1, Shahin Akhondzadeh1*

Abstract

Objective: Although the pathogenesis of schizophrenia is still uncertain, a variety of predisposing mechanisms have been implicated including inflammatory cascades. The present study was conducted to investigate the effectiveness of acetaminophen as a cyclooxygenase inhibitor in treating patients with schizophrenia.

Method: A double-blind clinical trial was performed on 52 patients with chronic schizophrenia. Patients received risperidone (up to 6 mg/day) plus either acetaminophen (975mg/day) or placebo. Psychotic symptoms were assessed by the Positive and Negative Syndrome Scale (PANSS) at the onset of the trial, and at 2, 4, 6, and 8 weeks post therapy.

Results: Compared to the placebo group, the acetaminophen group showed no significant difference in any subtypes of PANSS. Moreover, the side effect profiles of the 2treatment regimens were not significantly different.

Conclusion: Acetaminophen adjuvant to risperidone showed no significant effect in ameliorating symptoms of schizophrenia.

Trial Registration: The trial was registered at the Iranian Registry of Clinical Trials (registration number: IRCT201410251556N67).

Key words: Acetaminophen, Cyclooxygenase, Inflammation, PANSS, Schizophrenia

Schizophrenia is one of the most severe psychiatric disorders, with a psychopathology that remains uncertain. One theory implicated immunological dysfunctions, such as altered immune cell activities and heightened peripheral and central inflammatory responses in the pathogenesis of schizophrenia (1-3). Evidence of activation of inflammatory processes has been found in postmortem CNS tissue of patients with schizophrenia (4), including changes in cytokine levels and increased cyclooxygenase-2 (COX-2) expression (5, 6). Another line of evidence comes from observations of the therapeutic effects of COX-2 inhibitor medications, such as celecoxib, in patients with schizophrenia. Celecoxib was effective in the treatment of schizophrenia, while tested as an adjuvant agent to different antipsychotics, including risperidone (7, 8), amisulpride (9) and olanzapine (10). However, the degree of inflammatory cascade involvement and the best choice of anti-inflammatory agents to accompany the antipsychotic medication have remained controversial. The efficacy of celecoxib was inversely correlated to the duration of the disease; the effect was more pronounced in the acute phase of schizophrenia, but was not observed in patients with chronic schizophrenia (7, 9-10). When aspirin, another COX inhibitor, was added to antipsychotics as adjuvant treatment for schizophrenia spectrum disorders, it reduced symptoms of total and positive subscale of PANSS in these patients (12).

1. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.
2. Behavioral Disorders and Substance Abuse Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.

*Corresponding Author:
Address: Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran, Iran, 13337.
Tel: 98-2155412222, Fax: +98-2155419113, Email: s.akhond@neda.net

Article Information:
Received Date: 2017/07/01, Revised Date: 2017/10/12, Accepted Date: 2017/12/15
Minocycline inhibits cytokine production and reduces COX-2 expression and prostaglandin E2 production (13, 14).

Two randomized, double-blind, placebo-controlled studies supported minocycline's effect in reduction of positive and negative symptoms of chronic schizophrenia (15, 16).

Acetaminophen is one of the most commonly used antipyretic and analgesic agents worldwide (17). It is absorbed rapidly by the intestinal lumen and metabolized predominantly by the liver with half-life of 2 to 3 hours in adults (18).

Acetaminophen crosses the blood brain barrier easily and is evenly spread throughout the central nervous system, where selectively inhibit both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. Hence and acetaminophen predominantly shows its anti-inflammatory and analgesic effects in the brain (19, 20).

Falloon et al. conducted a clinical trial to assess the efficacy of acetaminophen in reducing the acute symptoms of schizophrenia and found that acetaminophen was not different from placebo (21). However, acetaminophen was administered to 10 patients for a short period of time, which was not an augmentation therapy. In addition, the patients received haloperidol as their behavior became unmanageable.

Having knowledge about the effects of administering the COX-1 and COX-2 inhibitors in treatment of schizophrenia, we hypothesized that extended administration of acetaminophen may reduce the symptoms of schizophrenia, when used as an adjuvant agent to antipsychotics. To test this hypothesis, we aimed at determining the effects of acetaminophen as adjuvant to risperidone in patients with chronic schizophrenia and exploring the effects of acetaminophen on positive, negative, and general behavioral symptoms of schizophrenia in a randomized, double-blind, placebo-controlled clinical trial.

Materials and Methods

Participants

This was a prospective, 8-week, double-blind study of parallel groups of patients with chronic schizophrenia. The patients were recruited from the pool of patients receiving inpatient treatment at Roozbeh Psychiatric hospital in Tehran, Iran, and at the Department of Psychiatry, Hamadan University of Medical Sciences, Hamadan, Iran, from December 2014 to October 2016. The trial protocol was approved by the Institutional Review Board (IRB) of Tehran University of Medical Sciences (Grant No: 26263) and was conducted in accordance with the Declaration of Helsinki and its subsequent revisions. The trial was registered at the Iranian Registry of Clinical Trials (www.irct.ir; registration number: IRCT201410251556N67). Written informed consent was obtained from all eligible patients and/or their legally authorized representatives. Patients were informed that they were free to withdraw from the study at any time without any influence on their relationship with their healthcare provider.

At the beginning of the study, 92 patients with the diagnosis of chronic schizophrenia were screened. Considering the inclusion and exclusion criteria, 36 candidates were omitted. The remaining 56 patients were randomly assigned into 2 groups. During the 8-week follow-up period, 2 patients dropped out of each group (Figure 1).

Inclusion Criteria

The inclusion criterion in this study was the diagnosis of schizophrenia using the Structured Clinical Interview for Axis I DSM-V Disorders (SCID). The Persian version of SCID shows kappa of 0.4 (acceptable) for diagnosis of psychiatric disorders (22) and has been used for diagnosis of schizophrenia in multiple previous trials in Iran (8, 23). All participants were inpatients, in the active phase of illness, aged 19 to 54 years, and all met the DSM-V criteria for schizophrenia. At the admission time, patients underwent a physical examination; moreover, blood and urine samples were taken from all the participants; furthermore, complete blood count, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (Cr) were also checked in all participants. All patients were free of any infection and autoimmune disease for at least 2 weeks before entering the trial, they had normal complete blood counts, hepatic, and renal panels, and negative toxicological screens. A minimum score of 60 on the Positive and Negative Syndrome Scale (PANSS) was required to enter the study (24).

Patients did not receive neuroleptics from 1 week prior to entering into the trial or depot neuroleptic at least 2 months before the study. Two senior residents of psychiatry performed the structured clinical interview for DSM-V (SCID) in patients’ native language, Farsi. Eligible participants in the study were 56 patients with chronic schizophrenia.

Exclusion Criteria

Patients were excluded from the study if they had a clinically significant organic or neurological disorder identified by a thorough physical examination, drug abuse, or dependence within the past 6 months, or any psychotic disorder other than schizophrenia. Pregnant or lactating women and those of reproductive age without adequate contraception were also excluded. Patients with significant depression, defined as a score ≥ 14 on the 17-item Hamilton Depression Rating Scale (HDRS) (Hamilton 1960), or a score of ≥ 4 on the depression item of PANSS were excluded from the study. Patients were also excluded if they had received electroconvulsive therapy (ECT) during the last 2 weeks prior to entering the trial. Patients did not use antidepressants, mood stabilizers, or a second antipsychotic (as an augmentative strategy) during the course of the trial.
Intervention
Patients were randomly allocated into 2 groups: 28 patients were allocated to the risperidone (6 mg/day) plus acetaminophen (975 mg/day; 325 mg t.i.d) group, and 28 patients were allocated to the risperidone (6 mg/day) plus placebo group for an 8-week therapy. Starting dosage of risperidone was 2 mg/day and was increased, with 2 mg increments, to 6 mg/day daily dosage for the first 2 days. Patients in the placebo group received 3 identical capsules a day. Patients also received biperiden if they showed extrapyramidal symptoms. Patients were assessed by a psychiatrist at baseline and at 2, 4, 6, and 8 weeks after medication administration.

Outcome
The principal measure of the outcome was the Positive and Negative Syndrome Scale (PANSS). This instrument is a standard scale for measuring severity of symptoms of patients with schizophrenia. The rater used standardized instructions when using the PANSS (24). Reliability and validity of the PANSS scale for patients with schizophrenia have been approved by its inventor with high internal consistency and inverse correlation of positive and negative symptoms (24); the alpha Cronbach for this instrument in Persian studies has been reported to be between 73% to 83% (25). The mean decrease in PANSS score from baseline was used as the main outcome measure of response to treatment.

The extrapyramidal symptoms were assessed using the extra pyramidal Symptoms Rating Scale (ESRS) (part one: Parkinsonism, dystonia, dyskinesia, and tardive dyskinesia (TD); its reliability and validity have been approved by high inter-rater reliability coefficient (80%≤) and concurrent validity of having more than 96% agreement between defined cases by DSM-IV TD criteria (26). PANSS and ESRS have been used in a number of previous trials in Iran (27, 28). PANSS and ESRS were rated by 2 trained senior residents of psychiatry. These tests were performed in patients’ native language, Farsi. Side effects were systematically recorded throughout the study and were assessed using a checklist (29) administered by a resident of psychiatry. All assessments were performed at baseline and at weeks 2, 4, 6 and 8. In addition, HDRS was administered at baseline and Week 8 to assess changes in depressive symptoms. This clinician-rated scale contains 17 questions (measured on either 3- or 5-point scales), which assess the severity of depression-related symptoms; its validity in measuring the symptoms of depression has been approved by Hamilton 1960 (30). The Persian version of HDRS test was validated and applied in a number of previous trials in Iran (31, 32).

Sample Size
A sample size of 46 was calculated (23 in each group) assuming to find a final difference of 4 scores on the PANSS rating scale, with type I error of 0.05, and power of 90% (according to the pilot study of this research). Considering an attrition rate of 10%, a final sample size of 50 was needed (25 in each group).

Randomization, Allocation, Concealment, and Blinding
Patients were randomized to receive acetaminophen or placebo in a 1:1 ratio using a computer-generated code. Throughout the study, the person, who administrated the medications, the rater, and the patients were blind to assignments.

Statistical Analysis
A two-way repeated measures analysis of variance (time×treatment interaction) was used. The two groups were considered as a between-subjects factor (group) and the 5 measurements during the treatment were considered as the within-subjects factor (time). This was done for positive, negative, general psychopathology subscale, and PANSS total scores. A Greenhouse–Geisser correction was used for sphericity. An unpaired student's t test with a two-sided p-value was used to compare the 2 groups at baseline and to determine the outcome of the 2 groups at the end of the trial. Fisher’s exact test was performed to compare the demographic data and frequency of side effects between protocols.

Results

Demographic Data
A total of 26 participants aged 19 to 54 finished the study in each group. There were no significant differences in baseline demographic data between the 2 groups (acetaminophen vs. placebo; Table 1).

PANSS Positive Subscale
Baseline PANSS positive subscale scores were not significantly different between the 2 groups (Table 1). General linear model repeated measures demonstrated no significant effect for time × treatment interaction on PANSS positive subscale scores [F (1.83, 91.70) = 2.40, P = 0.10] (Figure 2A). Comparison of PANSS positive subscale scores showed no significant differences between the 2 groups, except at Week 8 (Table 2).

PANSS Negative Subscale
Baseline PANSS negative subscale scores were not significantly different between the 2 groups (Table 1). General linear model repeated measures demonstrated a significant effect for time × treatment interaction on PANSS negative subscale scores [F (2.14, 107.41) = 2.25, P = 0.10] (Figure 2B). Comparison of PANSS negative subscale scores revealed no significant difference between the 2 groups (Table 2).
PANSS General Psychopathology Subscale
Baseline PANSS general psychopathology scores were not significantly different between the 2 groups (Table 1). General linear model repeated measures demonstrated no significant effect for time × treatment interaction on PANSS general psychopathology subscales scores [F (1.74, 87.44) = 1.83, P = 0.17] (Figure 2C). Comparison of PANSS general psychopathology subscale scores revealed no significant difference between the 2 groups (Table 2).

PANSS Total Score
Baseline PANSS total scores were not significantly different between the 2 groups (Table 1). General linear model repeated measures demonstrated no significant effect for time × treatment interaction on PANSS total scores [F (1.65, 82.86) = 3.09, P = 0.60] (Figure 2D). Comparison of PANSS total scores showed no significant difference between the 2 groups (Table 2).

Hamilton Depression Rating Scale (HDRS)
Baseline Hamilton Depression Rating Scale (HDRS) scores were not significantly different between the 2 groups (Table 1). Baseline mean HDRS scores were below 14 in both groups, which indicated no significant depressive symptoms in patients. No significant difference was observed between the 2 treatment groups on reduction of HDRS scores from baseline to the study end point [MD (95% CI) = -0.15 (-0.55 to 0.24), t (50) = -0.77, P = 0.44].

Extrapyramidal Symptoms Rating Scale (ESRS)
ESRS scores did not differ significantly between the study groups at baseline (Table 1). No significant effect was observed for time × treatment interaction in the ESRS scores [F (2.73, 136.48) = 1.52, P = 0.21]. The difference was not significant between treatment groups in score change from baseline to the endpoint [MD (95% CI) = -1.84 (-4.12 to 0.43), t (50) = -1.62, P = 0.11].

Adverse Events
No deaths or serious adverse events requiring medical intervention were reported. According to the adverse events checklist, there was no significant difference between the 2 groups in the frequency of adverse events (Table 3).

| Variable                          | Acetaminophen (N / mean ± SD) | Placebo (N / mean ± SD) | P-value |
|----------------------------------|-------------------------------|-------------------------|---------|
| Gender                           |                               |                         |         |
| Female                           | 10 (10.00 ± 7.05)             | 12 (11.04 ± 9.52)       | ns      |
| Male                             | 16 (16.04 ± 9.52)             | 14 (13.00 ± 7.05)       |         |
| Age (year)                       | 32.00 ± 7.05                  | 33.04 ± 9.52            | ns      |
| Marital status                   |                               |                         |         |
| Single                           | 16 (16.04 ± 9.52)             | 15 (14.00 ± 7.05)       |         |
| Married                          | 8 (8.00 ± 7.05)               | 9 (9.04 ± 9.52)         | ns      |
| Divorced                         | 2 (2.00 ± 2.15)               | 2 (2.00 ± 1.52)         |         |
| Level of education               |                               |                         |         |
| Illiterate                       | 1 (1.00 ± 1.00)               | 1 (1.00 ± 1.00)         |         |
| Primary school                   | 12 (12.04 ± 9.52)             | 11 (10.00 ± 7.05)       |         |
| High school diploma              | 8 (8.00 ± 7.05)               | 7 (7.04 ± 9.52)         | ns      |
| University degree                | 5 (5.00 ± 5.00)               | 7 (7.04 ± 9.52)         |         |
| Smoking, n,                      | 22 (22.00 ± 14.06)            | 23 (23.00 ± 15.00)      | ns      |
| Duration of illness (years)      | 78.54 ± 41.61                 | 80.38 ± 46.61           | ns      |
| Type of schizophrenia            |                               |                         |         |
| Paranoid                         | 14 (14.00 ± 7.05)             | 15 (15.04 ± 9.52)       |         |
| Residual                         | 4 (4.00 ± 4.00)               | 3 (3.04 ± 3.52)         |         |
| Disorganized                     | 4 (4.00 ± 4.00)               | 4 (4.04 ± 3.52)         | ns      |
| Undifferentiated                 | 4 (4.00 ± 4.00)               | 4 (4.04 ± 3.52)         |         |
| Prior antipsychotic medications  |                               |                         |         |
| Risperidone                      | 15 (15.00 ± 7.05)             | 16 (16.04 ± 9.52)       |         |
| Haloperidol                      | 8 (8.00 ± 7.05)               | 9 (9.04 ± 9.52)         |         |
| Fluphenazine                     | 6 (6.00 ± 6.00)               | 6 (6.04 ± 5.52)         | ns      |
| Olanzapine                       | 9 (9.00 ± 9.05)               | 10 (10.04 ± 9.52)       |         |
| Baseline scores                  |                               |                         |         |
| PANSS total score                | 109.58 ± 12.76                | 107.96 ± 10.10          | ns      |
| PANSS positive subscale          | 29.77 ± 5.33                  | 29.33 ± 4.04            |         |
| PANSS negative subscale          | 27.04 ± 4.64                  | 26.23 ± 4.66            |         |
| PANSS general psychopathology subscale | 52.96 ± 8.88 | 52.50 ± 6.39 | ns |
| HDRS                             | 8.08 ± 1.78                   | 7.46 ± 1.72             |         |
| ESRS                             | 2.50 ± 4.65                   | 1.62 ± 2.95             |         |

SD, standard deviation; PANSS, Positive and Negative Syndrome Scale; HDRS, Hamilton Depression Rating Scale; ESRS, Extrapyramidal Symptom Rating Scale; N, number; ns, not significant
Table 2. Comparison of PANSS Total and Subscale Scores in the Treatment Groups

| Measurement                        | Acetaminophen + risperidone (mean ± SD) | Placebo + risperidone (mean ± SD) | t (50) | P- value | Cohen’s d |
|------------------------------------|----------------------------------------|-----------------------------------|--------|----------|-----------|
| PANSS total score                  |                                        |                                   |        |          |           |
| Week 2                             | 95.69 ± 16.06                          | 96.23 ± 8.77                      | 0.15   | 0.88     | 0.04      |
| Week 4                             | 79.54 ± 14.06                          | 85.35 ± 6.68                      | 1.90   | 0.06     | 0.53      |
| Week 6                             | 68.04 ± 12.89                          | 73.08 ± 8.88                      | 1.64   | 0.10     | 0.46      |
| Week 8                             | 57.58 ± 11.82                          | 63.19 ± 9.81                      | 1.86   | 0.06     | 0.52      |
| PANSS positive subscale score      |                                        |                                   |        |          |           |
| Week 2                             | 24.58 ± 5.60                           | 25.00 ± 3.67                      | 0.32   | 0.74     | 0.09      |
| Week 4                             | 19.65 ± 4.46                           | 21.12 ± 3.05                      | 1.47   | 0.14     | 0.41      |
| Week 6                             | 15.50 ± 2.84                           | 16.54 ± 3.04                      | 1.26   | 0.21     | 0.35      |
| Week 8                             | 10.50 ± 2.55                           | 13.35 ± 3.80                      | 3.16   | 0.003    | 0.89      |
| PANSS negative subscale score      |                                        |                                   |        |          |           |
| Week 2                             | 23.73 ± 4.53                           | 23.46 ± 3.67                      | -0.21  | 0.82     | -0.06     |
| Week 4                             | 19.96 ± 4.46                           | 21.27 ± 3.08                      | 1.22   | 0.22     | 0.34      |
| Week 6                             | 18.04 ± 3.96                           | 18.92 ± 3.45                      | 0.85   | 0.39     | 0.24      |
| Week 8                             | 16.08 ± 3.50                           | 17.15 ± 3.64                      | 1.08   | 0.28     | 0.30      |
| PANSS general psychopathology subscale score |                                |                                   |        |          |           |
| Week 2                             | 47.38 ± 9.88                           | 47.38 ± 6.29                      | 0      | 1.00     | 0         |
| Week 4                             | 40.04 ± 8.26                           | 43.00 ± 6.00                      | 1.47   | 0.14     | 0.36      |
| Week 6                             | 34.62 ± 7.93                           | 37.69 ± 5.74                      | 1.60   | 0.11     | 0.45      |
| Week 8                             | 30.54 ± 8.46                           | 32.81 ± 5.25                      | 1.16   | 0.25     | 0.32      |

PANSS, positive and negative syndrome scale; SD, standard deviation; * statistically significant

Table 3. Frequency of Adverse Events in the Study of Acetaminophen and Risperidone in Chronic Schizophrenia

| Side effect          | Risperidone + acetaminophen | Risperidone + placebo | P- Value (Fisher exact test) |
|----------------------|----------------------------|-----------------------|-----------------------------|
| Constipation         | 2 (7.69%)                  | 0 (0%)                | 0.490*                      |
| Tremor               | 1 (3.85%)                  | 1 (3.85%)             | 0.999*                      |
| Increased Appetite   | 2 (7.69%)                  | 2 (7.69%)             | 0.999*                      |
| Loss of appetite     | 3 (11.54%)                 | 1 (3.85%)             | 0.610*                      |
| Fatigue              | 1 (3.85%)                  | 3 (11.54%)            | 0.610*                      |
| Dry mouth            | 4 (15.38%)                 | 6 (23.08%)            | 0.726*                      |
| Sedation             | 4 (15.38%)                 | 3 (11.54%)            | 0.999*                      |
| Dizziness            | 5 (19.23%)                 | 4 (15.38%)            | 0.999*                      |
| Vomiting             | 2 (7.69%)                  | 3 (11.54%)            | 0.999*                      |
| Nausea               | 1 (3.85%)                  | 2 (7.69%)             | 0.999*                      |
| Headache             | 1 (3.85%)                  | 2 (7.69%)             | 0.999*                      |
| Abdominal pain       | 2 (7.69%)                  | 3 (11.54%)            | 0.999*                      |
| Diarrhea             | 3 (11.54%)                 | 2 (7.69%)             | 0.999*                      |

*Not Significant

Discussion

The inflammatory cascades have been implicated in the psychopathology of schizophrenia. The aim of our study was to investigate the effectiveness of acetaminophen as a cyclooxygenase inhibitor in the treatment of patients with schizophrenia. Acetaminophen inhibits both isoforms of cyclooxygenase (COX-1 and COX-2) primarily in the central nervous system, causing an increase in the pain threshold. Acetaminophen shows 4-fold selectivity for COX-2, causing an almost complete inhibition of COX-2 and a moderate inhibition of COX-1 (33). No significant effect of acetaminophen was found in symptoms of schizophrenia as measured by different subscales of PANSS.

Our results are consistent with a previous study which reported no significant effect of acetaminophen on acute symptoms of schizophrenia (21). Falloon et al. suggest that the florid psychotic phenomena may be related to an excess of prostaglandin E in the hypothalamus (34). Therefore, they performed this trial on 10 patients with schizophrenia in a cross-over trial. Administration of acetaminophen (1g q.i.d) for 1 week was not more effective than placebo in resolving acute symptoms of schizophrenia (21).
A review of the literature reveals controversies in the effectiveness of anti-inflammatory agents in general, and COX-2 inhibitors in particular, in treatment of schizophrenia. Muller et al. found a beneficial effect of the COX-2 inhibitor, celecoxib, add-on in the treatment of schizophrenia (9). Rapaport et al. observed no therapeutic effect of celecoxib augmentation on any aspects of psychopathology in continuously ill outpatients with schizophrenia (11). The study of Rapaport et al. involved a group of outpatients with chronic schizophrenia, while Muller et al. investigated in patients with acute exacerbation of the disease. It is possible that celecoxib augmentation potentiates the speed of response, but not the overall magnitude of response. Rapaport concluded that the benefit of celecoxib augmentation for those with an acute psychotic exacerbation cannot be extended to continuously symptomatic outpatients with schizophrenia (11). Contrary to this conclusion, Akhondzadeh et al. showed the effectiveness of celecoxib add-on to risperidone in attenuating positive and general psychopathology, as well as PANSS total score on a group of patients with chronic schizophrenia (8).

This controversy is also reflected in Sommer et al.’s review of anti-inflammatory agents in treatment of schizophrenia. Five studies that administered celecoxib as a COX-2 inhibitor produced heterogeneous results varying from strong positive effect to strong negative effect. The overall analysis of the data revealed an effect size of 0.15, which was not statistically significant (35). Consistent with this review, Yokoto et al. found that COX-2 was not involved in pathophysiology of schizophrenia. Immunohistochemical analysis of neuronal COX-2 expression in the hippocampus showed no up-regulation of COX2 in patients with schizophrenia (36). This finding suggests that any potential effect of celecoxib in attenuating symptoms of schizophrenia may be via COX-2 independent pathways.

Like acetaminophen, aspirin affects COX-1 and COX-2. However, aspirin’s effect on COX-1 is irreversible and it does not pass the blood brain barrier. Two previous studies in the literature used aspirin as an adjuvant therapy for conventional treatment of patients with chronic schizophrenia. The accumulative results showed an effect size of 0.3, which was statistically significant (35). Accumulative evidence on therapeutic effects of different anti-inflammatory agents in patients with schizophrenia showed potential positive effects of aspirin, N-acetyl cysteine and estrogens, when added to antipsychotic treatment. However, as these agents are all broadly active substances, the beneficial effects on symptom severity may not be mediated by their anti-inflammatory aspects (11).

Figure 1. Flowdiagram of the Patients Enrolment in the Study
Limitation

One limitation of the current study was that it included a sample of inpatients only. Future studies with a larger number of inpatients as well as outpatients can help generalize the findings. Another limitation of our study was the lack of measurement of biological parameters, such as IL-2, IL-6, TNF-alpha, and toxoplasma gondii antibodies, as quantitative indicators of inflammatory cascade. Future follow-up studies that measure these biomarkers could better characterize the effect of acetaminophen adjuvant used for the patient group.

Conclusion

This study revealed no significant role for acetaminophen as adjunct to risperidone in the treatment of patients with schizophrenia. This finding adds to the controversy around the use of COX-2 inhibitor agents for treatment of schizophrenia. Future studies with larger number of patients that are combined with a basic immunohistochemistry assessment may help resolve this controversy.

Acknowledgment

This study was a part of Dr. Abolfazl Ehyaii’s postgraduate thesis toward the Iranian Board of Psychiatry and was supported by a grant from Tehran University of Medical Sciences to Prof. Shahin Akhondzadeh (Grant No: 26263). The funding organization had no role in any part of this study including designing and conducting the study, data collection, analysis, and interpretation, preparation, review, or approval of the manuscript, or even the decision to submit the paper for publication.

Conflict of Interest

No conflict of interest associated with the manuscript existed for any of the authors, and there was no source of extra institutional commercial funding. The funding organization had no role in conducting any part of the study (designing and conducting the study; data collection, analysis, and interpretation; preparation, review, or approval of the manuscript; and nor in the decision to submit the paper for publication).

References

1. Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, Mccrossin T, et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry 2013; 18: 206-214.
2. Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull 2013; 39: 1174-1179.
3. Akhondzadeh S. The 5-htr hypothesis of schizophrenia. IDrugs 2001; 4: 295-300.
4. Korschenhausen DA, Hample HJ, Ackenheil M, Penning R, Muller N. Fibrin degradation products in post mortem brain tissue of schizophrenics: A possible marker for underlying inflammatory processes. Schizophr Res 1996; 19: 103-109.
5. Muller N, Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 2006; 10: 131-148.
6. Muller N, Schwarz MJ. Cox-2 inhibition in schizophrenia and major depression. Curr Pharm Des 2008; 14: 1452-1465.
7. Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002; 159: 1029-1034.
8. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr Res 2007; 90: 179-185.
9. Muller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, et al. Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpiride treatment. Schizophr Res 2010; 121: 118-124.
10. Baheti T, Nischal A, Nischal A, Khattri S, Arya A, Tripathi A, et al. A study to evaluate the effect of celecoxib as add-on to olanzapine therapy in schizophrenia. Schizophr Res 2013; 147: 201-202.
11. Rapaport MH, Delrahim KK, Breslin CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 2005; 57: 1594-1596.
12. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71: 520-527.
13. Lai AY, Todd KG. Hypoxia-activated microglial mediators of neuronal survival are differentially regulated by tetracyclines. Glia 2006; 53: 809-816.
14. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 1998; 95: 15769-15774.
15. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71: 138-149.
16. Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, et al. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind
placebo-controlled study. Psychiatry Res 2014; 215: 540-546.

17. Schnitzer TJ. Update of acr guidelines for osteoarthritis: Role of the coxibs. J Pain Symptom Manage 2002; 23: S24-30; discussion S31-24.

18. Prescott LF. Kinetics and metabolism of paracetamol and phenacetin. Br J Clin Pharmacol 1980; 10 Suppl 2: 291s-298s.

19. Bottig RJ. Mechanism of action of acetaminophen: Is there a cyclooxygenase 3? Clin Infect Dis 2000; 31 Suppl 5: S202-210.

20. Ghanem CI, Perez MJ, Manaoutu JE, Mattot AD. Acetaminophen from liver to brain: New insights into drug pharmacological action and toxicity. Pharmaco Res 2016; 109: 119-131.

21. Falloon I, Watt DC, Lubbe K, Macdonald A, Shepherd M. N-acetyl-p-amino-phenol (paracetamol, acetaminophen) in the treatment of acute schizophrenia. Psychol Med 1978; 8: 495-499.

22. Sharifi V, Asadi SM, Mohammadi MR, Amini H, Kaviani H, Semnani Y, et al. Reliability and validity of persian version of Structured Clinical Interview for Axis I DSM-IV Disorders (SCID). advances in Cognitive Science. 2004; 6: 10-22.

23. Arabzadeh S, Amini H, Tehrani-Doost M, Sharifi V, Noroozian M, Rahiminejad F. Correlation of neurological soft signs and neurocognitive performance in first episode psychosis. Psychiatry Res 2014; 220: 81-88.

24. Kay SR, Fiszbein A, Opfer LA. The positive and negative syndrome scale (panss) for schizophrenia. Schizophr Bull 1987; 13: 261-276.

25. Bordbar F, Reza M, Abdollahian E, Hojat K, Samaric AA. Effects of selegiline on negative symptoms in schizophrenia: A double-blind clinical trial. Iranian Journal of Psychiatry and Clinical Psychology 2008; 14: 131-139.

26. Chouinard G, Margojele HC. Manual for the extrapyramidal symptom rating scale (ers). Schizophr Res 2005; 76: 247-265.

27. Zeinoddini A, Ahadi M, Farokhnia M, Rezaei F, Tabrizi M, Akhondzadeh S. L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: A double-blind, placebo-controlled, randomized trial. J Psychiatr Res 2014; 59: 125-131.

28. Amrollahi Z, Rezaei F, Salehi B, Modabbernia AH, Marouli A, Esfandiarí GR, et al. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord 2011; 129: 327-331.

29. Akhondzadeh S, Ahmadi-Abhari SA, Assadi SM, Shabestari OL, Kashani AR, Farzanehgan ZM. Double-blind randomized controlled trial of baclofen vs. Clonidine in the treatment of opiates withdrawal. J Clin Pharm Ther 2000; 25: 347-353.

30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.

31. Arabzadeh S, Ameli N, Zeinoddini A, Rezaei F, Farokhnia M, Mohammadinnejad P, et al. Celecoxib adjunctive therapy for acute bipolar...